Literature DB >> 7061180

Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms.

E Rey, P d'Athis, M O Richard, D de Lauture, G Olive.   

Abstract

The pharmacokinetic properties of a single 200-mg dose of tiapride were studied in eight healthy volunteers (four males and four females). The drug was administered by i. v., i. m., and p. o. routes (solution and tablets). Plasma and urine concentrations were determined by a high-performance liquid chromatography. The results were compatible with a linear two-compartment model. The half-life in the disposition phase ranged from 2.19 h to 4.55 h (mean 3.23 h). Peak plasma concentrations were always reached within 2 h. The percentage of absorption of the i. m. and the two p. o. formulations varied from 49.3 to 98.9%. The renal clearance varied from 11.8 to 24.9 l/h. The drug was mainly eliminated in unmetabolized form in the urine (75.6%).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061180

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  8 in total

1.  Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease.

Authors:  T Norman; E Chiu; R H James; M S Gregory
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease.

Authors:  R A Roos; E J de Haas; O J Buruma; F A de Wolff
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  A new oral formulation of tiapride (drops): pharmacokinetic profile and therapeutic applications.

Authors:  M Canal; C R Desanti; J P Santoni
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 4.  Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation.

Authors:  J W Steele; D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 5.  Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.

Authors:  D H Peters; D Faulds
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

6.  Opposing effects of dopamine antagonism in a motor sequence task-tiapride increases cortical excitability and impairs motor learning.

Authors:  Silke Lissek; Guido S Vallana; Lara Schlaffke; Melanie Lenz; Hubert R Dinse; Martin Tegenthoff
Journal:  Front Behav Neurosci       Date:  2014-06-19       Impact factor: 3.558

7.  The DA antagonist tiapride impairs context-related extinction learning in a novel context without affecting renewal.

Authors:  Silke Lissek; Benjamin Glaubitz; Oliver T Wolf; Martin Tegenthoff
Journal:  Front Behav Neurosci       Date:  2015-09-03       Impact factor: 3.558

8.  Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride.

Authors:  Stefanie Fekete; K Egberts; T Preissler; C Wewetzer; C Mehler-Wex; M Romanos; M Gerlach
Journal:  Eur J Clin Pharmacol       Date:  2020-09-28       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.